Response Biomedical has received the US Patent and Trademark Office (USPTO) notice of allowance on one of the company's patent applications regarding the RAMP (Rapid Analyte Measurement Platform) technology.
The patent entitled ‘Comparative Multiple Analyte Immunoassay’ is expected to issue in the first quarter of 2011.
Response Biomedical chief scientific officer Paul Harris said they are pleased to see this patent issued in the US and the patent will allow the company to use the RAMP method to measure the relative amounts of two or more analytes with much more accuracy, than if the analytes were first measured and then the amounts compared.
"This increased accuracy is the result of not having to have standard curves. Instead the amounts are compared directly to each other," Harris said.
Response Biomedical CEO Wayne Kay said as they focus on building our cardiac business in the US and abroad, these patents further strengthen the compelling offering to our growing customer base.
"This patent also further builds on our solid and growing patent protection surrounding our innovative RAMP technology program," Kay said.